Grifols stock gains as Q3 cash flow supports debt reduction
Published on 11/09/2026 at 12:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrifols strengthens its balance sheet
- Third-quarter revenue exceeded consensus as Biopharma growth accelerated.
- Free cash flow and lower leverage improved the financial position.
- Management maintained full-year guidance despite weaker albumin sales in China.
- Investors are awaiting SPARTA Phase 3 results in the fourth quarter.
On November 2, Grifols reported stronger-than-expected third-quarter results, led by its Biopharma division. A Yahoo Finance report published November 3 said revenue reached 2.04 billion euros, above the 1.98 billion euro consensus estimate, while management maintained its full-year financial guidance.
Adjusted EBITDA rose 9.8 percent at constant currency to 538 million euros, lifting the margin to 26.4 percent. Net profit increased 27.9 percent to 162 million euros. The figures indicate that stronger sales in core plasma-derived therapies are translating into improved profitability, although the performance remains uneven across product categories.
Biopharma leads quarterly growth
Biopharma revenue increased 10.3 percent at constant currency. Immunoglobulin sales rose 11.3 percent, while subcutaneous immunoglobulin products grew 40.3 percent. Alpha-1 and specialty proteins revenue advanced 18.2 percent, supported in part by rabies-related products.
Albumin revenue declined 13.2 percent, with regulatory factors and elevated inventory levels in China weighing on demand. The weakness in China remains a key issue for investors because it offsets part of the growth in immunoglobulins and specialty proteins.
Cash flow supports deleveraging
Grifols generated 208 million euros in free cash flow before mergers and acquisitions during the quarter. Total net leverage fell to 3.98 times from 4.2 times a year earlier, while liquidity rose to 2.14 billion euros. The company also refinanced obligations due in 2027 and said it now faces no significant debt maturities until the fourth quarter of 2028.
For the first nine months, free cash flow before mergers and acquisitions reached 298 million euros, an increase of 59 percent year on year. Management said it remains confident in its 2026 free-cash-flow guidance, while the full-year adjusted EBITDA margin target remains 25 percent.
Grifols stock traded at 11.33 euros on Lang & Schwarz at 12:13 CET on Monday, November 9, 2026. Investors can follow the real-time quote of Grifols stock.
Pipeline and plasma supply remain in focus
Management expects topline results from the Phase 3 SPARTA study by the end of the fourth quarter. The outcome could provide a further clinical reference for the pipeline, but remains uncertain until the company releases the data.
Grifols is also expanding plasma collection in Egypt. The company targets approximately 1 million litres in 2026 and up to 3 million litres annually by 2029, supporting longer-term supply for its plasma-derived medicines business.
The broader Euro Stoxx 50 market provides the relevant regional context for European healthcare shares.
More news and analyses on Grifols stock will focus on cash conversion, Chinese albumin demand, plasma collection and the SPARTA readout.
Grifols company facts
- Company: Grifols, S.A.
- ISIN: ES0171996087
- Exchange quote: 11.33 euros on Lang & Schwarz, Monday, November 9, 2026, 12:13 CET
- Third-quarter revenue: 2.04 billion euros
- Adjusted EBITDA: 538 million euros; 26.4 percent margin
- Net leverage: 3.98 times
